Canada: Federal Court Dismisses Notion That Patents Should Be Given Only One Interpretation For All Purposes

Summary

In a pair of simultaneously released decisions on June 13, 2014, Justice O'Reilly allowed Allergan's applications (the "Applications") prohibiting the Minister of Health from issuing NOCs to Cobalt (now "Actavis") (2014 FC 566) and Apotex (2014 FC 567) to market their generic versions of LUMIGAN RC® until the expiry of Canadian Patent 2,585,691 (the "'691 Patent") in 2026.

Allergan was represented by Andrew Reddon, Steven Mason, Steven Tanner and Sanjaya Mendis of McCarthy Tétrault LLP.

Background

Allergan originally marketed a 0.03% bimatoprost ("Bp") containing formulation for treating glaucoma called LUMIGAN, which Justice O'Reilly referred to as "old Lumigan". Despite its potency, old Lumigan caused some dose-dependent side effects. Allergan subsequently developed an enhanced bimatoprost formulation which it marketed as LUMIGAN RC®, which Justice O'Reilly referred to as "new Lumigan".

Remarkably, new Lumigan contained only 1/3 the concentration of Bp as old Lumigan (0.01% vs. 0.03%), but was able to maintain comparable efficacy for treating glaucoma. The inventors of the '691 Patent were able to achieve this result through an inventive formulation.

Both Cobalt and Apotex sought early market entry to sell their respective generic versions of new Lumigan prior to the expiry of the '691 Patent, which gave rise to the Applications described herein. Both cases engaged the same claims of the '691 Patent. Both second persons raised similar issues, which were addressed by Justice O'Reilly.

Construction – Claims 16 and 19 of the '691 Patent

The '691 Patent is entitled, "Enhanced Bimatoprost Ophthalmic Solution". At the hearing, Allergan asserted only claims 16 and 19.

Justice O'Reilly found the claims at issue unambiguous, with claim 16 relating to a formulation with lower Bp (0.01%) and higher BAK (200 ppm) than old Lumigan (which had 0.03% and 50 ppm, respectively). Claim 19 was found to relate to the use of that formulation for treating glaucoma or intraocular hypertension.

Obviousness – Determining Inventive Concept a Separate Exercise from Claims Construction

Both Cobalt and Apotex argued that the '691 Patent should be given only one interpretation for all purposes – infringement, obviousness, and utility. The second persons thus alleged the inventive concept was simply the same as the claimed invention, meaning a formulation with 0.01% Bp and 200 ppm BAK, which they alleged was an obvious modification of old Lumigan.

Citing his own decision in Hoffman-La Roche (2011 FC 785), Justice O'Reilly held that the interpretation of a patent should be as consistent as possible across the various issues in play. However, Justice O'Reilly recognized that construing the inventive concept for the purpose of the obviousness analysis is a separate exercise from claims construction, meaning that the construction of the claims is not determinative of the inventive concept. This is particularly true where the claim relates to a bare list of ingredients or a bare chemical formula, requiring the skilled person to review the entire specification to determine the inventiveness of what is claimed.

In these cases, the inventive concept posited by Cobalt and Apotex ignored the in vitro and in vivo data contained in the patent which taught the skilled person that increasing BAK surprisingly resulted in greater Bp penetration into the eye. In reviewing the '691 Patent as a whole, Justice O'Reilly found the inventive concept of claims 16 and 19 to be a formulation with reduced Bp but with comparable efficacy to old Lumigan, achieved by increasing BAK.

Justice O'Reilly further found that there were significant differences between the inventive concept of the claims and the state of the art at the relevant time, which differences would not have been obvious to the skilled person.

Sound Prediction – Sound Line of Reasoning Implicit in Data

Justice O'Reilly also held that the experimental data disclosed in the '691 Patent provided a sufficient factual basis to soundly predict that new Lumigan would deliver a comparable effect to old Lumigan despite only having one-third the amount of Bp.

While the patent did not specifically make a correlation between the disclosed in vitro and in vivo studies, Justice O'Reilly accepted the reasoning of Allergan's experts that the skilled person would have easily interpreted the data to arrive at the necessary prediction. In doing so, Justice O'Reilly found the sound line of reasoning implicit in the data itself as it would have been readily apparent to the skilled reader; it did not have to be explicitly laid out in the patent.

Anticipation – Broad Generalized Disclosure not Enabling

Both Cobalt and Apotex alleged the '691 Patent was anticipated by an earlier compound patent claiming the old Lumigan formulation. These patents disclosed a very general class of compounds and formulations for a broad array of indications that the generics alleged encompassed the formulation of new Lumigan.

Justice O'Reilly found that the patents failed to disclose new Lumigan's special advantage (embodied in claims 16 and 19) of being able to effectively lower intraocular pressure while using a fraction of the active ingredient usually required for a similar result. In addition, Justice O'Reilly held that the disclosures were not enabling as required by Sanofi (2008 SCC 61). This decision accords with Justice Hughes' reasoning in Combigan (2012 FC 767), where he held that a patent with broad generalized disclosure did not disclose and enable the specific formulation at issue.

Conclusion – Critical to Review Patent as a Whole

Justice O'Reilly's decision underscores the critical distinction between claims construction and determining the inventive concept of the claims of the patent, which are separate tasks. This distinction is particularly important where the patent relates to a bare formulation or a bare chemical formula.

To view original article, please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Norton Rose Fulbright Canada LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Norton Rose Fulbright Canada LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions